{"id":"NCT00298038","sponsor":"Bausch Health Americas, Inc.","briefTitle":"A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12-19","primaryCompletion":"2008-08-15","completion":"2008-08-15","firstPosted":"2006-03-01","resultsPosted":"2019-08-14","lastUpdate":"2019-09-18"},"enrollment":299,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatic Encephalopathy"],"interventions":[{"type":"DRUG","name":"Rifaximin","otherNames":["XifaxanÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rifaximin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).","primaryOutcome":{"measure":"Time To The First Breakthrough Overt HE Episode","timeFrame":"Baseline up to 6 Months (168 days)","effectByArm":[{"arm":"Rifaximin","deltaMin":13,"sd":null},{"arm":"Placebo","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["37467180","30283499","21848797","20335583"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":140},"commonTop":["Nausea","Diarrhoea","Fatigue","Oedema peripheral","Headache"]}}